Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,301 total articles
Itochu is likely to use its upcoming IR Day to sharpen capital-allocation messaging. The company has a strong free-cash-flow profile and a history of shareholder returns; a clear commitment to larger buybacks or accelerated returns would re-rate sentiment. This trade targets an entry at $19.50 with a $23.00 target and a $17.00 stop, for a long-term…
UroGen's Zusduri is moving from clinical novelty to commercial staple. Recent reimbursement wins and a sharp revenue ramp ($51M in Q1; +152% YoY) suggest the therapy is being adopted into urology workflows. Given a market cap near $2.01B and elevated short interest, the setup favors a long trade sized for a mid-to-long-term horizon, with clear entr…
Palantir is trading at $136.20 after strong momentum and accelerating commercial adoption. The company sits at the intersection of large-scale data integration, AI orchestration and mission-critical workflows for government and enterprise clients. Fundamentals show positive free cash flow ($2.69B) and high retention metrics cited by analysts; valua…
Tesla is trading at $373.57 with a market cap near $1.40T and stretched multiples, but the macro push to reshore high-value manufacturing combined with early commercial strides in Optimus creates an asymmetric opportunity. This trade targets a re-rating into $460 over the next 180 trading days, with a defined stop at $325 to protect against executi…
Compa Compania de Minas Buenaventura looks undervalued relative to its earnings power and the operational catalysts coming into play. At a current price o…
CAE has traded below its near-term averages while clearing key operational headwinds from 2024 impairments. With recurring training revenue, partnerships (including urban air mobility), and a $7.9B market cap that looks reasonable versus recovery optionality, we upgrade CAE to Strong Buy and lay out a clear entry, stop and target for a long trade o…
Agnico Eagle's strategic expansion in Finland is a multi-year value driver that should gradually lower unit costs and extend mine life. This trade idea takes a long position to capture upside as construction milestones, reserve updates, and higher realized gold prices re-rate the stock. Entry, stop and target defined with a long-term horizon and cl…
Quanterix (QTRX) trades near $3.84 with an enterprise value roughly equal to one year of sales. The hardware and ultra-sensitive biomarker franchise gives the company an asymmetric setup: meaningful upside if clinical and commercial adoption continues, limited near-term downside if a deal or improving sales re-rate multiples. This is a tactical lon…
Dorian LPG (LPG) is benefitting from a structural squeeze in LPG shipping capacity and a spike in spot freight. With a market cap near $1.85B, a conservative balance sheet (debt/equity ~0.49), free cash flow of ~$116M and a forward-looking dividend cadence, the stock still has room to run. Technical momentum and compressed valuation metrics vs. cyc…
UiPath has moved from proof-of-concept losses to positive GAAP operating income while ARR and revenue expansion are starting to reflect real product-market fit for agentic automation. At roughly $6.4B market cap, the stock offers a favorable risk-reward: operational profitability, healthy free cash flow, and a valuation that still leaves upside if …
We recommend a tactical long in iHeartMedia (IHRT) at current levels. The company is cheaply valued by equity market cap ($599M) and sits near the low end of its 52-week range, while H2 ad seasonality, podcast monetization and reported M&A interest create catalysts for a re-rating. Trade plan: enter at $3.95, stop $3.40, target $5.25 over a mid-ter…
Realty Income offers a 5%+ yield, a conservative balance sheet (debt/equity ~0.76), industry-leading occupancy and a clear path to total return through dividend compounding and modest multiple expansion. This trade idea lays out an actionable entry at $65.21, a $75 target in 180 trading days and a $60 stop-loss, with catalysts and risks spelled out…
Arcturus (ARCT) has plunged to its 52-week low after a year of churn. With a market cap under $200M, negative enterprise value and a recently approved self-amplifying mRNA COVID vaccine in Europe, this is a high-risk, high-upside buy-and-hold setup. Entry $5.84, stop $4.80, target $12.00 across a long-term (180 trading days) horizon.
Lumentum (LITE) sold off with the wider AI-tech rotation but the underlying drivers - hyperscaler capex, Nvidia investment and a multi-year silicon photonics cycle - remain intact. At a $61.5B market cap and with clearly visible cash flow growth potential, I upgrade to Buy and enter at current levels with a $1,050 target and $720 stop for a 180-tra…
NPK International (NPKI) is a capital-intensive provider of recyclable composite matting and site services. The stock is trading near $14.36 with a $1.21B market cap, modest leverage, and positive free cash flow. If recent fleet investment slows, FCF yield could improve materially, supporting either shareholder returns or margin expansion. This tra…
Advanced Micro Devices is playing a meaningful role in the AI server arms race. With revenue momentum, a growing data-center mix, and visible free cash flow, AMD looks positioned to continue share gains. Valuation is rich today, so this trade pairs a measured entry with a tight stop and a realistic target over a 180 trading-day horizon.
Franco-Nevada (FNV) is a top-tier precious-metals royalty company trading around $200.24 with a $38.7B market cap. The business combines defensive cash flow, growth optionality from streaming deals, and exposure to a gold market that looks structurally tight. Valuation is rich on cash-flow multiples, but a near-term pullback and improving catalysts…
Prudential Financial (PRU) combines a near-5% yield with a conservative valuation (P/E ~12, P/B ~1.29) and steady insurance cash generation. We upgrade to Buy and lay out a two-stage trade: a mid-term income capture to $130 and a longer-term rerating target to $145, with a clear stop at $109 to protect capital.
Amadeus IT Group's ADR trading on the OTC market has drifted to the mid-$50s. Technicals show a base forming around the 10-day and 20-day averages while fundamental visibility is limited on the ticker — yet the market's short bias and thin liquidity have produced a valuation that looks compelling for a disciplined, event-driven long. This trade lay…
Dolby is trading near the bottom of its 52-week range on a sensible valuation: P/E ~19, EV/EBITDA ~11 and free cash flow of roughly $301M. With Q3 2025 revenue momentum, a 2.8% dividend yield and modest technical oversold signals, I see an asymmetric risk/reward heading into earnings. This is a tactical, mid-term long for disciplined traders.
Nvidia remains richly priced but the company’s earnings power, cash flow generation, and dominant AI GPU share argue this is not a classic bubble. This trade idea proposes a measured long entry around $206 with a stop at $192 and a target of $260 over a long-term horizon (180 trading days), balancing upside from continued AI adoption against valuat…
Apple's next product push into China - dubbed here 'Apple Smart' - could be an important near-term catalyst on top of durable fundamentals: $129B in free cash flow, a $4.83T market cap, and technical momentum. This trade idea targets a measured entry at $329.00 with a $345.00 take-profit and a $315.00 stop, for a mid-term holding of 45 trading days…
Nvidia's stock has pulled back into the low $200s after a period of strength. Fundamentals remain intact: dominant AI inference share, enormous free cash flow, and low leverage. Valuation is rich but reasonable against growth and profitability. This trade idea recommends a tactical long into the pause with a measured stop and two-stage targets acro…
ImmunityBio (IBRX) has moved from a damaged narrative after an FDA warning letter to a constructive setup following sBLA acceptance and strong comparative data for ANKTIVA. The stock is expensive on sales but meaningful clinical progress and a clear regulatory timeline create an asymmetric trade through the PDUFA on 01/06/2027. I upgrade my stance …
CareDx is reshaping itself into a higher-growth testing services and digital-solutions company. Recent preliminary results showing 39% revenue growth (Testing Services +48%) and the $170M sale of Lab Products give the company financial flexibility. Coupled with early momentum tied to Naveris integration, I view the risk/reward as attractive from cu…
